Literature DB >> 1908385

A comparison of buccal nitroglycerin and sublingual nitroglycerin in the prophylaxis and treatment of exertional (situation-provoked) angina pectoris.

C L Bray1, S Jain, E B Faragher, A Myers, P Myers, P MacIntyre, A Rae, M Goldman, M Alcorn.   

Abstract

Suscard is a buccally administered formulation which provides rapid introduction of nitroglycerin directly into the systemic circulation and, by virtue of its sustained-release properties, may confer protection against anginal attacks for several hours. Its efficacy has been established in angina pectoris and more recently its usefulness has been extended to include the management of unstable angina and acute heart failure. Buccal nitroglycerin combines the possibilities of short-term treatment and more extended prophylaxis. In a multicentre double-blind study the efficacy of buccal nitroglycerin and sublingual nitroglycerin were compared in patients with proven chronic stable exercise-induced angina as regards anginal attacks and capacity for physical activity. The conclusion is that the two formulations of nitroglycerin have a comparable effect in the treatment of acute attacks of angina pectoris. Buccal nitroglycerin has many advantages when used prophylactically. This is documented by less frequent anginal attacks and a more prolonged duration of effect resulting in an increased physical activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1908385

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  2 in total

1.  Buccaling under the pressure: influence of secondary care establishments on the prescribing of glyceryl trinitrate buccal tablets in primary care.

Authors:  A J Pryce; H F Heatlie; S R Chapman
Journal:  BMJ       Date:  1996 Dec 21-28

2.  Pharmacological Characterization of Orofacial Nociception in Female Rats Following Nitroglycerin Administration.

Authors:  Robert M Caudle; Stephanie L Caudle; Natalie D Flenor; Eric L Rohrs; John K Neubert
Journal:  Front Pharmacol       Date:  2020-12-03       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.